{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:51:47Z","timestamp":1765889507072,"version":"build-2065373602"},"reference-count":56,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Early detection and the rise of targeted cancer treatment have led to increased overall survival and decreased mortality among cancer patients. As the cancer survivor population ages, there is an increased risk for cardiovascular disease due to pre-existing comorbidities, deconditioning during therapy, or the natural progression of aging. Furthermore, with emerging oncologic therapies, there is an increased recognition of their potential cardiovascular toxicities. Indeed, heart disease is the leading cause of death in cancer survivors, which may reflect upon both the success of novel oncologic therapies and their potential cardiovascular toxicities. This recognition has driven the development of cardio-oncology, a multi-disciplinary field that involves collaboration between hematologists, oncologists, and cardiologists to screen, prevent, and manage cardiovascular disease in cancer patients and cancer survivors. The field focuses on early cardiovascular detection and prevention for these patients before, during, and after their oncologic treatment. As oncologic therapies evolve and our knowledge of short- and long-term adverse cardiovascular effects grows, it is critical for physicians to identify those at risk for increased morbidity and mortality, while also balancing the importance of their oncologic treatment plan. Multimodality cardiac imaging is the crux of the diagnosis and surveillance of these patients within cardio-oncology, and includes echocardiography, nuclear, computed tomography (CT), and cardiac magnetic resonance (CMR). Cardiac imaging is essential to establish the baseline function and assess various cardiotoxicities, including left ventricular dysfunction, heart failure, atherosclerosis, vascular injury, and arrhythmias. This review will discuss common oncologic therapies and their cardiotoxic profiles, the cardiac multimodality imaging modalities used in cardio-oncology, and the various approaches for the diagnosis and surveillance of this population.<\/jats:p>","DOI":"10.3390\/jcm14124353","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T05:08:39Z","timestamp":1750309719000},"page":"4353","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardio-Oncology and Multi-Imaging Modalities"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-5307","authenticated-orcid":false,"given":"Christine M.","family":"Park","sequence":"first","affiliation":[{"name":"Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Lerman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0799-4805","authenticated-orcid":false,"given":"Felipe","family":"Contreras Yametti","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Garcia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3091-3735","authenticated-orcid":false,"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-4188","authenticated-orcid":false,"given":"Aldo L.","family":"Schenone","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Gongora","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining Cardiovascular Toxicities of Cancer Therapies: An International Cardio-Oncology Society (IC-OS) Consensus Statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and Management of Patients with Heart Disease and Cancer: Cardio-Oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-Induced Cardiotoxicity: A Review of Clinical Risk Factors, Pharmacologic Prevention, and Cardiotoxicity of Other HER2-Directed Therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10557-021-07181-3","article-title":"The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: An Updated Review","volume":"36","author":"Wu","year":"2022","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in Patients Treated with Immune Checkpoint Inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular Magnetic Resonance in Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Frascaro, F., Bianchi, N., Sanguettoli, F., Marchini, F., Meossi, S., Zanarelli, L., Tonet, E., Serenelli, M., Guardigli, G., and Campo, G. (2023). Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. J. Clin. Med., 12.","DOI":"10.3390\/jcm12247737"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement from the American Heart Association","volume":"144","author":"Fradley","year":"2021","journal-title":"Circulation"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","article-title":"Cardiotoxicity with Vascular Endothelial Growth Factor Inhibitor Therapy","volume":"2","author":"Touyz","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/CIRCULATIONAHA.115.018351","article-title":"Cardiovascular Complications of Novel Multiple Myeloma Treatments","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11886-021-01441-2","article-title":"5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death","volume":"23","author":"More","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11864-021-00868-7","article-title":"Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation","volume":"22","author":"Ell","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11936-017-0535-5","article-title":"Ischemic Heart Disease: Special Considerations in Cardio-Oncology","volume":"19","author":"Giza","year":"2017","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2021.01.011","article-title":"BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and\/or Trastuzumab","volume":"3","author":"Dobson","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pcad.2025.01.001","article-title":"Global Longitudinal Strain as an Early Marker of Cardiac Damage after Cardiotoxic Medications, a State of the Art Review","volume":"89","author":"Sartorio","year":"2025","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients during and after Cancer Chemotherapy: A Systematic Review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaccao.2020.10.011","article-title":"Strain Imaging in Cardio-Oncology","volume":"2","author":"Liu","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e230048","DOI":"10.1148\/ryct.230048","article-title":"Echocardiography versus Cardiac MRI for Measurement of Left Ventricular Ejection Fraction in Individuals with Cancer and Suspected Cardiotoxicity","volume":"6","author":"Nazir","year":"2024","journal-title":"Radiol. Cardiothorac. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lorenzo-Esteller, L., Ramos-Polo, R., Pons Riverola, A., Morillas, H., Berdejo, J., Pernas, S., Pomares, H., Asiain, L., Garay, A., and Martinez Perez, E. (2024). Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment. Cancers, 16.","DOI":"10.3390\/cancers16203466"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"14","DOI":"10.15420\/cfr.2018:24:2","article-title":"Left Ventricular Dysfunction in the Setting of Takotsubo Cardiomyopathy: A Review of Clinical Patterns and Practical Implications","volume":"4","author":"Yalta","year":"2018","journal-title":"Card. Fail. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement from the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients with Immune Checkpoint Inhibitor-Associated Myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation","volume":"72","author":"Ferreira","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e014283","DOI":"10.1161\/CIRCIMAGING.122.014283","article-title":"Cardiac Magnetic Resonance Imaging Techniques and Applications for Pericardial Diseases","volume":"15","author":"Wang","year":"2022","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jaccao.2021.09.010","article-title":"Cardiac Computed Tomography in Cardio-Oncology","volume":"3","author":"Yang","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/RTI.0000000000000297","article-title":"Appropriate Use Criteria for Cardiac Computed Tomography: Does Computed Tomography Have Incremental Value in All Appropriate Use Criteria Categories?","volume":"33","author":"Erthal","year":"2018","journal-title":"J. Thorac. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Milazzo, V., Cosentino, N., Campodonico, J., Lucci, C., Cardinale, D., Cipolla, C.M., and Marenzi, G. (2020). Characteristics, Management, and Outcomes of Acute Coronary Syndrome Patients with Cancer. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113642"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2018.10.056","article-title":"Comparison of Coronary Computed Tomography Angiography, Fractional Flow Reserve, and Perfusion Imaging for Ischemia Diagnosis","volume":"73","author":"Driessen","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaccao.2020.05.009","article-title":"Cardiac Tumors","volume":"2","author":"Tyebally","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaccao.2024.09.006","article-title":"Multimodality Imaging in the Diagnostic Work-Up of Patients with Cardiac Masses","volume":"6","author":"Angeli","year":"2024","journal-title":"JACC CardioOncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jcmg.2018.01.015","article-title":"Abnormalities in 3-Dimensional Left Ventricular Mechanics with Anthracycline Chemotherapy Are Associated with Systolic and Diastolic Dysfunction","volume":"11","author":"Zhang","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pcad.2024.07.002","article-title":"Anthracyclines, Diastolic Dysfunction and the Road to Heart Failure in Cancer Survivors: An Untold Story","volume":"86","author":"Camilli","year":"2024","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","article-title":"Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1beta and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity","volume":"105","author":"Sawyer","year":"2002","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: JACC: CardioOncology State-of-the-Art Review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s11912-024-01599-2","article-title":"Risk Stratification, Screening and Treatment of BRAF\/MEK Inhibitors-Associated Cardiotoxicity","volume":"26","author":"Senechal","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular Adverse Events Associated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity Associated with Tyrosine Kinase Inhibitor Sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ctrv.2017.07.006","article-title":"Incidence and Risk of Cardiotoxicity in Cancer Patients Treated with Targeted Therapies","volume":"59","author":"Santoni","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd4476","article-title":"The Immune Checkpoint Inhibitors: Where Are We Now?","volume":"13","author":"Webster","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T Cell Therapy: Current Limitations and Potential Strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/clc.20904","article-title":"Melphalan-Induced Supraventricular Tachycardia: Incidence and Risk Factors","volume":"34","author":"Feliz","year":"2011","journal-title":"Clin. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2324709613480346","DOI":"10.1177\/2324709613480346","article-title":"Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management","volume":"1","author":"Dhesi","year":"2013","journal-title":"J. Investig. Med. High Impact Case Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaccao.2019.09.007","article-title":"Cancer Therapy-Related Cardiac Dysfunction of Nonanthracycline Chemotherapeutics: What Is the Evidence?","volume":"1","author":"Kamphuis","year":"2019","journal-title":"JACC CardioOncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Gongora, C.A. (2024). Are Sodium-Glucose Cotransporter-2 Inhibitors the Cherry on Top of Cardio-Oncology Care?. Cardiovasc. Drugs Ther., 1\u20138.","DOI":"10.1007\/s10557-024-07604-x"},{"key":"ref_55","first-page":"559","article-title":"Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated with Anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"J. Am. Coll. Cardiol. Heart Fail."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Maamari, D.J., Biddinger, K.J., Jurgens, S.J., R\u00e4m\u00f6, J.T., Zheng, A., Hayes, D., Gongora, C.A., Choi, S.H., Arany, Z., and Thavendiranathan, P. (2025). Polygenic Susceptibility to Dilated Cardiomyopathy Underlies Peripartum, Alcohol-Induced, and Cancer Therapy-Related Cardiomyopathies. medRxiv.","DOI":"10.1101\/2025.02.17.25321705"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4353\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:54:31Z","timestamp":1760032471000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/12\/4353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":56,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["jcm14124353"],"URL":"https:\/\/doi.org\/10.3390\/jcm14124353","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,6,18]]}}}